While sexism exists in all strands of society, where in 2023, women earn 77 cents for every dollar earned by men, studies estimate that it will take the world 257…
An oral drug developed by the Swiss company ObsEva was shown to reduce menstrual bleeding and pain caused by uterine fibroids. The phase III trial tested ObsEva’s drug candidate linzagolix…
Yesterday, Swiss biotech ObsEva highlighted positive Phase III results that show their fertility treatment nolasiban improved the pregnancy rate of women following in vitro fertilization. ObsEva, a clinical stage, Geneva-based biopharmaceutical…
Ernest Loumaye began as a doctor at a university hospital and is now CEO of ObsEva. We chatted about how biotech supports women’s health. ObsEva, one of the top biotechs…
Geneva is the largest city in French-speaking Switzerland, a financial powerhouse, home to the United Nations and known as the "Peace Capital." Can the city's biotech industry justify its high profile?…
UPDATE (07/03/2017): ObsEva has announced the start of its Phase III trials for nolasiban, an oral oxytocin receptor antagonist. It is under evaluation for improvements in pregnancy and live birth rates following embryo…